16,582 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Daiichi Life Insurance Co. Ltd.

Key Points

• Daiichi Life Insurance acquired 16,582 Thermo Fisher Scientific shares worth approximately $8.3 million in the second quarter. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported quarterly EPS of $6.03 and revenue of $11.99 billion, exceeding analyst estimates; revenue increased 10.5% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $619.41.
• TMO shares opened at $629.02, near their 52-week high of $643.99. The company also declared a quarterly dividend of $0.47 per share, equivalent to a 0.3% yield.

Daiichi Life Insurance Co. Ltd. acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 16,582 shares of the medical research company's stock, valued at approximately $8,314,000.

Other hedge funds have also made changes to their positions in the company. North Dakota State Investment Board acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $7,505,000. BlackRock Inc. acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth $15,501,867,000. Hudson Value Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 24.9% during the 2nd quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company's stock valued at $8,349,000 after purchasing an additional 3,317 shares in the last quarter. Xponance LLC lifted its stake in shares of Thermo Fisher Scientific by 8.1% in the 4th quarter. Xponance LLC now owns 59,295 shares of the medical research company's stock valued at $34,358,000 after purchasing an additional 4,436 shares during the last quarter. Finally, Annex Advisory Services LLC boosted its holdings in Thermo Fisher Scientific by 12.6% in the second quarter. Annex Advisory Services LLC now owns 24,656 shares of the medical research company's stock worth $12,361,000 after purchasing an additional 2,756 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Up 0.2%

Shares of NYSE:TMO opened at $629.02 on Friday. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $643.99. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The company has a market cap of $232.58 billion, a P/E ratio of 33.84, a P/E/G ratio of 2.56 and a beta of 0.85. The stock's 50-day moving average is $542.53 and its 200-day moving average is $509.70.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.11%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on TMO shares. Jefferies Financial Group restated a "buy" rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Weiss Ratings raised Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, July 14th. Royal Bank Of Canada raised their price objective on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a research note on Friday, July 24th. KeyCorp reaffirmed an "overweight" rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Finally, HSBC downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating and lowered their price target for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and a consensus target price of $619.41.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Michael D. Shafer sold 25,500 shares of the company's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president directly owned 20,994 shares in the company, valued at $12,596,400. This represents a 54.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $574.47, for a total transaction of $5,744,700.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company's stock, valued at approximately $71,191,194.75. This trade represents a 7.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 63,493 shares of company stock valued at $37,657,681 in the last three months. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source